{
    "root": "254b26fa-28c4-4a9e-9df7-c9747829eaee",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "NuvaRing",
    "value": "20250321",
    "ingredients": [
        {
            "name": "ETONOGESTREL",
            "code": "304GTH6RNH"
        },
        {
            "name": "ETHINYL ESTRADIOL",
            "code": "423D2T571U"
        },
        {
            "name": "ETHYLENE-VINYL ACETATE COPOLYMER (28% VINYL ACETATE)",
            "code": "8ILA5X28VS"
        },
        {
            "name": "ETHYLENE-VINYL ACETATE COPOLYMER (9% VINYLACETATE)",
            "code": "4OKC630HS6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        }
    ],
    "indications": "FOR VAGINAL USE ONLY\n                  \n                  NuvaRingÂ® is indicated for use by females of reproductive age to prevent pregnancy.",
    "contraindications": "One NuvaRing is inserted in the vagina. The ring must remain in place continuously for three weeks, followed by a one-week ring-free interval. ( 2 )",
    "warningsAndPrecautions": "Each NuvaRing (etonogestrel/ethinyl estradiol vaginal ring) is individually packaged in a reclosable aluminum laminate sachet consisting of three layers, from outside to inside: polyester, aluminum foil, and low-density polyethylene. The ring should be replaced in this reclosable sachet after use and discarded in a waste receptacle out of the reach of children and pets. It should not be flushed down the toilet.\n                  \n                     \n                     \n                     \n                        \n                           Box of 3 sachets\n                           NDC 59212-146-03",
    "adverseReactions": "NuvaRing is contraindicated in females who are known to have or develop the following conditions:\n                  \n                     A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: \t\t\t\t\t\t\n                           Smoke, if over age 35 [see Boxed Warning and Warnings and Precautions (5.1)]\n                           \n                           Have deep vein thrombosis or pulmonary embolism, now or in the past [see Warnings and Precautions (5.1)]\n                           \n                           Have cerebrovascular disease [see Warnings and Precautions (5.1)]\n                           \n                           Have coronary artery disease [see Warnings and Precautions (5.1)]\n                           \n                           Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see Warnings and Precautions (5.1)]\n                           \n                           Have inherited or acquired hypercoagulopathies [see Warnings and Precautions (5.1)]\n                           \n                           Have uncontrolled hypertension [see Warnings and Precautions (5.5)]\n                           \n                           Have diabetes mellitus with vascular disease [see Warnings and Precautions (5.9)]\n                           \n                           Have headaches with focal neurological symptoms or migraine headaches with aura [see Warnings and Precautions (5.10)]\n                              \n                                 Women over age 35 with any migraine headaches [see Warnings and Precautions (5.10)]\n                                 \n                              \n                           \n                        \n                     \n                     Liver tumors, benign or malignant or liver disease [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)]\n                     \n                     Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.11)]\n                     \n                     Pregnancy, because there is no reason to use CHCs during pregnancy [see Use in Specific Populations (8.1)]\n                     \n                     Current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see Warnings and Precautions (5.14)]\n                     \n                     Hypersensitivity reactions, including anaphylaxis and angioedema, to any of the components of NuvaRing [see Warnings and Precautions (5.6) and Adverse Reactions (6)]\n                     \n                     Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to potential for ALT elevations [see Warnings and Precautions (5.4) and Drug Interactions (7)]"
}